Litcius/Paper detail

Double-Blind, Placebo-Controlled Study of E-B-FAHF-2 in Combination With Omalizumab-Facilitated Multiallergen Oral Immunotherapy

Julie Wang, Robert A. Wood, Samantha Raymond, Mayte Suárez‐Fariñas, Nan Yang, Scott H. Sicherer, Hugh A. Sampson, Xiu-Min Li

2023The Journal of Allergy and Clinical Immunology In Practice17 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboOmalizumabDesensitization (medicine)Adverse effectRandomized controlled trialInternal medicineAllergyOral immunotherapyOral food challengeDouble blindFood allergyGastroenterologySurgeryImmunoglobulin EImmunologyAntibodyPathologyAlternative medicineReceptorFood Allergy and Anaphylaxis ResearchAllergic Rhinitis and SensitizationUrticaria and Related Conditions
Double-Blind, Placebo-Controlled Study of E-B-FAHF-2 in Combination With Omalizumab-Facilitated Multiallergen Oral Immunotherapy | Litcius